Description

Avertid (Betahistine) Solution for Oral Use 8 mg/ml. 60 ml. №1

Ingredients:

Each ml contains 8 mg of Betahistine dihydrochloride as the active ingredient.

Dosage:

The recommended dosage is determined by a healthcare professional. Typically, the starting dose is 16 mg three times a day, which can be increased gradually.

Indications:

Avertid is indicated for the treatment of Meniere’s disease and vertigo. It works by improving blood flow in the inner ear, reducing the pressure of the endolymphatic fluid.

Contraindications:

Do not use Avertid if you are allergic to Betahistine or any other ingredients in the solution. It is not recommended for use during pregnancy or breastfeeding.

Directions:

Shake the bottle well before use. Measure the prescribed dose using the provided dropper and take it orally. It can be taken with or without food.

Scientific Evidence:

Studies have shown that Betahistine, the active ingredient in Avertid, effectively reduces the frequency and severity of vertigo attacks in patients with Meniere’s disease. Research published in the International Journal of Audiology demonstrated a significant improvement in vertigo symptoms with Betahistine treatment.

Additional Information:

It is important to follow the dosage instructions provided by your healthcare provider to achieve the best results with Avertid. Some common side effects may include headache, nausea, and stomach upset. If you experience any severe side effects, contact your doctor immediately.

Pharmacologically, Betahistine acts as a histamine analog that functions as a weak agonist at the H1 receptor and a strong antagonist at the H3 receptor. This dual action results in increased blood flow in the inner ear, which helps to alleviate symptoms of vertigo and balance disorders.

Clinical trials have shown that Avertid is well-tolerated and effective in reducing the frequency and severity of vertigo attacks. In a randomized controlled trial published in the Journal of Neurology, Neurosurgery & Psychiatry, patients treated with Betahistine experienced a significant decrease in the number of vertigo episodes compared to the placebo group.